Design an antibiotic effective against most infections … – News SIN – National Information Services

Photo

INTERNATIONAL WRITING -. An international team of researchers has developed a new antibiotic that has proven effective against Staphylococcus aureus, the bacteria responsible for much of the infections contracted in hospitals and resistant to almost all antibiotics microorganism.

The new antibiotic derived from quinazolinones, has been designed by an international consortium led by the University of Notre Dame (Indiana, USA) in which participated the Institute of Physical Chemistry of the CSIC Rocasolano.

The resistance of bacteria to antibiotics is a global health problem each Once more disturbing: “Fewer and fewer new antibiotics and super-resistant pathogens,” explains researcher at the Department of Crystallography of CSIC, Juan A. Hermoso, one of the study authors

resistant Staphylococcus aureus. aureus (MRSA) generates skin diseases, meningitis, endocarditis, pneumonia or sepsis, but especially this organism is involved in most of the infections contracted after an intervention or hospitalization.

This bacteria lives on the skin and mucous membranes of humans, allowing you to enter (and infect) with relative ease the bloodstream of a patient recently underwent surgery, through contact with the medical staff, with another patient or even a contaminated object.

just over a year ago, the same research team now published their discovery in the Journal of the American Chemical Society, described the mechanism that enables this pathogen is resistant any antibiotic.

And the MRSA has a unique protein called PBP2a remodeling and rebuild the wall of staphylococci. However, this protein is completely resistant to beta-lactam antibiotics, which are the most used in the world and that block the action of proteins as PBP2a remodel the bacterial wall.

In the original investigation, scientists discovered that PBP2a has “a specific site (called allosteric site) that functions as a switch: if it does not light, the protein is not active and can not be blocked by antibiotics,” says Fair. Now, these same researchers have gone a step further, and from that information have designed a new type of antibiotic that works against the MDR pathogen.

Now, these same researchers have gone a step further, and from such information have designed a new type of antibiotic that works against the MDR pathogen.

Using techniques of X-ray crystallography, researchers have determined how the structure of this molecule and found that “squeezes Switch allosteric site and off point that needs to be bacteria resistant to antibiotics. “

With this, researchers have not only confirmed the value of the original article, but have also provided a new molecule that will be the basis for a new class of specific antibiotics against these multidrug-resistant pathogen.

The molecule, which has already been tested in mice, is a new type of antibiotic (derived from quinazolinones) that blocks the regeneration of the cell wall with a completely different system using beta-lactams.

In addition, eligible to generate a new family of potent antibiotics can eliminate infections caused by this aggressive pathogen and, though still a long way from clinical trials, “the molecule pharmacokinetic meets all conditions (requirements) required to go into production for humans,” says Hermoso

. Source: 20minutes .com